Intellia Therapeutics ( ($NTLA) ) has provided an update. On November 8, 2025, Intellia Therapeutics announced positive results from its Phase 1/2 ...

The convergence of AI, quantum computing, and biosciences is propelling the global healthcare industry into a new era - now projected to surpass US$1.7 trillion in AI-driven biotech spending by 2025, ...

Researchers have developed a synthetic regeneration system for genetically editing crops, avoiding the challenging step of ...

The company scans entire proteins with CRISPR to find functional vulnerabilities, then hunts for molecules that exploit them ...

Access to ERS Genomics’ foundational CRISPR/Cas9 patent portfolio expands our genetic engineering toolkit and strengthens our ability to speed up and optimize strain development across Dyadic’s ...

Phase 1 data showed CRISPR’s one-time treatment, CTX310, produced sharp, dose-dependent reductions in triglycerides and LDL cholesterol with a strong safety profile. ・The company plans to advance the ...

Life sciences revolve around many living forms such as humans, plants, animals, and microorganisms. The discoveries made ...

Yi Li, professor of horticultural plant breeding biotechnology in the College of Agriculture, Health and Natural Resources ...

A new gene-editing technique enables the correction of multiple genetic mutations simultaneously, transforming the prospects ...

An experimental gene-editing therapy developed by Crispr Therapeutics is showing promise for treating heart disease.

CRISPR Therapeutics (CRSP) posts new data from an early stage trial for CTX310, an in vivo gene editing therapy for heart ...

A CRISPR-based gene editing therapy dramatically reduced levels of LDL cholesterol and triglycerides in patients with heart ...